X4 Pharmaceuticals (XFOR) Cash & Equivalents (2018 - 2025)
Historic Cash & Equivalents for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to $69.6 million.
- X4 Pharmaceuticals' Cash & Equivalents fell 2851.8% to $69.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.6 million, marking a year-over-year decrease of 2851.8%. This contributed to the annual value of $55.7 million for FY2024, which is 4386.09% down from last year.
- According to the latest figures from Q3 2025, X4 Pharmaceuticals' Cash & Equivalents is $69.6 million, which was down 2851.8% from $39.2 million recorded in Q2 2025.
- Over the past 5 years, X4 Pharmaceuticals' Cash & Equivalents peaked at $147.2 million during Q2 2024, and registered a low of $39.2 million during Q2 2025.
- Its 5-year average for Cash & Equivalents is $87.1 million, with a median of $81.8 million in 2021.
- Its Cash & Equivalents has fluctuated over the past 5 years, first soared by 18782.28% in 2023, then plummeted by 7335.92% in 2025.
- X4 Pharmaceuticals' Cash & Equivalents (Quarter) stood at $81.8 million in 2021, then soared by 48.82% to $121.7 million in 2022, then dropped by 18.49% to $99.2 million in 2023, then plummeted by 43.86% to $55.7 million in 2024, then rose by 25.01% to $69.6 million in 2025.
- Its Cash & Equivalents was $69.6 million in Q3 2025, compared to $39.2 million in Q2 2025 and $40.3 million in Q1 2025.